Get the latest ISIS - Isis Pharmaceuticals Inc. stock market performance data and financial news.
Mipomersen lowers cholesterol but not without liver side effects.. Check out TheStreet for the latest stock market news and financial investment headlines.
ISIS-FXIRx to Treat Clotting Disorders. Check out TheStreet for the latest stock market news and financial investment headlines.
Isis climbs on news it will benefit financially from a deal between Alnylam and Takeda.. Check out TheStreet for the latest stock market news and financial investment headlines.
http://www.thestreet.com/story/10418548/1/health-winners-losers-isis.html
. Check out TheStreet for the latest stock market news and financial investment headlines.
. Check out TheStreet for the latest stock market news and financial investment headlines.
Cholesterol drug mipomersen reached main goal in late stage trial, Isis and Genzyme say. Check out TheStreet for the latest stock market news and financial investment headlines.
http://www.thestreet.com/story/10503544/1/genzyme-and-isis-say-cholesterol-drug-met-goal.html
The biotech rises on a narrowed first-quarter loss.. Check out TheStreet for the latest stock market news and financial investment headlines.
http://www.thestreet.com/story/10416406/1/health-winners-losers-isis.html
Genzyme-Isis Deal Detailed, Details from an SEC filing reveal the
licensing pact for mipomersen may not be overly pricey. ...
http://www.thestreet.com/p/newsanalysis/biotech/10397798.html
How Mighty Is Isis?, The biotech soars on promising drug results, but can its
fundamentals endure? ... Print This Story. How Mighty Is Isis? ...
http://www.thestreet.com/p/newsanalysis/investing/10322093.html
Connect with TheStreet